{"nctId":"NCT02375971","briefTitle":"RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity","startDateStruct":{"date":"2015-12-30","type":"ACTUAL"},"conditions":["Retinopathy of Prematurity"],"count":224,"armGroups":[{"label":"Ranibizumab 0.2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab"]},{"label":"Ranibizumab 0.1 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab"]},{"label":"Laser therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Laser therapy"]}],"interventions":[{"name":"Ranibizumab","otherNames":[]},{"name":"Laser therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* preterm infants with a birth weight of less than 1500 g\n* bilateral ROP with one of the following retinal findings in each eye: Zone I, stage 1+, 2+, 3 or 3+ disease, or Zone II, stage 3+ disease, or Aggressive posterior retinopathy of prematurity (AP-ROP)\n\nExclusion Criteria:\n\n* ROP disease characteristic in either eye other than that listed above at the time of the first investigational treatment\n* A history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes\n* Had received any previous surgical or nonsurgical treatment for ROP (e.g., ablative laser therapy or cryotherapy, vitrectomy)\n* Had been previously exposed to any intravitreal or systemic anti-VEGF agent (either the patient or the mother during this child's pregnancy)\n* Had used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever was longer\n* Had ocular structural abnormalities that were assessed by the Investigator to have had a clinically significant impact on study assessments\n* Had active ocular infection within 5 days before or on the day of first investigational treatment\n* Had a history of hydrocephalus requiring treatment\n* Had a history of any other neurological conditions that are assessed by the Investigator to have a significant risk of severe impact on visual function\n* Had any other medical conditions or clinically significant comorbidities or personal circumstances that were assessed by the Investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments (e.g., poor life expectancy, pupil not able to be adequately dilated, unable to comply with the visit schedule)","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24","description":"To achieve this outcome, patients must fulfill all the following criteria, 1) survival, 2) no intervention with a second modality for ROP, 3) absence of active ROP and 4) absence of unfavorable structural outcome. Retinopathy of prematurity (ROP) is a pathologic process that occurs in the incompletely vascularized, developing retina of low birth-weight preterm neonates.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"75.0","spread":null},{"groupId":"OG002","value":"66.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Interventions With a Second Modality for ROP at Week 24","description":"Intervention for ROP in either eye at or before the 24-week assessment visit with a treatment modality other than the modality of the first study treatment. Only descriptive analysis done.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":null},{"groupId":"OG001","value":"16.9","spread":null},{"groupId":"OG002","value":"24.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing an Event, From the First Study Treatment to the Last Study Visit","description":"An event was defined as death, treatment switch, or the first occurrence of unfavorable structural outcomes in either eye. Only descriptive analysis done.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Having Recurrent ROP and Receiving Any Post-baseline Intervention at or Before Week 24","description":"Recurrence of ROP is defined as subjects receiving any post-baseline intervention in either eye at or before 24 weeks (ranibizumab re-treatment or switch to laser in the ranibizumab groups, switch to ranibizumab treatment in the laser group). Zone I consists of a circle, the radius of which extends from the center of the optic disc to twice the distance from the center of the optic disc to the center of the macula. Zone II extends centrifugally from the edge of zone I to the nasal ora serrata. Only descriptive analysis done.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":null},{"groupId":"OG001","value":"31.2","spread":null},{"groupId":"OG002","value":"18.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null},{"groupId":"OG001","value":"53.3","spread":null},{"groupId":"OG002","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"17.4","spread":null},{"groupId":"OG002","value":"13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Ocular Adverse Events by Primary System Organ (SOCs) at Week 24","description":"Percent of Participants with Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"32.9","spread":null},{"groupId":"OG002","value":"17.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"6.6","spread":null},{"groupId":"OG002","value":"13.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Ranibizumab Concentration in Pharmacokinetic Serum Samples Over Time at Day 1, Day 15 and Day 29","description":"Blood samples for the determination of ranibizumab concentrations were collected in the Ranibizumab treatment arms only at the following time points: within 24 hours after the first administration of ranibizumab, at Day 15 and at Day 29. Only descriptive analysis done.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24700.0","spread":"52400.00"},{"groupId":"OG001","value":"12100.0","spread":"25500.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5830.0","spread":"4750.0"},{"groupId":"OG001","value":"27700.0","spread":"144000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1810.0","spread":"2990.0"},{"groupId":"OG001","value":"732.0","spread":"535.0"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Vascular Endothelial Growth Factor (VEGF) Levels Over Time at Day 1, Day 15 and Day 29","description":"Blood samples for the determination of systemic VEGF levels were collected at the following time points: before the first investigational treatment, at Day 15 and at Day 29. Only descriptive analysis done.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"239.0","spread":"226.0"},{"groupId":"OG001","value":"230.0","spread":"224.0"},{"groupId":"OG002","value":"232.0","spread":"240.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239.0","spread":"226.0"},{"groupId":"OG001","value":"239.0","spread":"233.0"},{"groupId":"OG002","value":"233.0","spread":"245.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"466.0","spread":"1500.0"},{"groupId":"OG001","value":"118.0","spread":"129.0"},{"groupId":"OG002","value":"180.0","spread":"214.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"498.0","spread":"1560.0"},{"groupId":"OG001","value":"124.0","spread":"134.0"},{"groupId":"OG002","value":"177.0","spread":"224.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117.0","spread":"84.0"},{"groupId":"OG001","value":"176.0","spread":"142.0"},{"groupId":"OG002","value":"161.0","spread":"132.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117.0","spread":"84.0"},{"groupId":"OG001","value":"139.0","spread":"75.3"},{"groupId":"OG002","value":"163.0","spread":"138.0"}]}]}]},{"type":"SECONDARY","title":"Total Number of Ranibizumab Injections Received at Week 24","description":"Patients randomized to receive Ranibizumab 0.1 mg or 0.2 mg received a single dose of intravitreal Ranibizumab to each eye on Day 1 (Baseline). Only descriptive analysis done.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants With Non-Ocular Adverse Events by Primary System Organ (SOCs) at Week 24","description":"Percent of Participants with Non-Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.0","spread":null},{"groupId":"OG001","value":"27.6","spread":null},{"groupId":"OG002","value":"31.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":null},{"groupId":"OG001","value":"34.2","spread":null},{"groupId":"OG002","value":"27.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"19.7","spread":null},{"groupId":"OG002","value":"17.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Vital Signs (Body Length, Head Circumference and Knee to Heel Length) at Day 85 and Day 169","description":"Body Length, Head Circumference and Knee to Heel Length were assessed. Only descriptive analysis done.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"2.59"},{"groupId":"OG001","value":"11.0","spread":"3.33"},{"groupId":"OG002","value":"11.1","spread":"3.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","spread":"3.28"},{"groupId":"OG001","value":"18.6","spread":"3.66"},{"groupId":"OG002","value":"19.0","spread":"4.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"1.96"},{"groupId":"OG001","value":"6.5","spread":"2.31"},{"groupId":"OG002","value":"7.2","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"2.12"},{"groupId":"OG001","value":"10.3","spread":"2.56"},{"groupId":"OG002","value":"10.6","spread":"2.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"1.90"},{"groupId":"OG001","value":"3.1","spread":"1.65"},{"groupId":"OG002","value":"3.1","spread":"2.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"2.86"},{"groupId":"OG001","value":"5.1","spread":"2.19"},{"groupId":"OG002","value":"5.3","spread":"2.15"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Vital Signs (Weight) at Day 85 and Day 169","description":"Body weight was measured. Only descriptive analysis done.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2198.9","spread":"615.68"},{"groupId":"OG001","value":"2149.9","spread":"754.27"},{"groupId":"OG002","value":"2182.7","spread":"612.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3794.3","spread":"782.48"},{"groupId":"OG001","value":"3716.7","spread":"897.15"},{"groupId":"OG002","value":"3826.0","spread":"882.17"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Vital Signs (Sitting Blood Pressure) at Day 85 and Day 169","description":"Blood Pressure measurements were not required by the protocol. Instead, the most recent Systolic and Diastolic Blood Pressure expressed in millimeters of mercury (mmHg) measured as part of the routine clinical care were used. Only descriptive analysis done.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"14.66"},{"groupId":"OG001","value":"7.0","spread":"14.25"},{"groupId":"OG002","value":"9.8","spread":"16.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"15.85"},{"groupId":"OG001","value":"9.4","spread":"15.73"},{"groupId":"OG002","value":"15.5","spread":"16.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"15.60"},{"groupId":"OG001","value":"11.8","spread":"14.42"},{"groupId":"OG002","value":"14.7","spread":"17.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"16.15"},{"groupId":"OG001","value":"11.2","spread":"13.45"},{"groupId":"OG002","value":"17.7","spread":"19.35"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":73},"commonTop":["Retinal haemorrhage","Pyrexia","Dermatitis diaper","Anaemia","Nasopharyngitis"]}}}